MOTS-c Benefits: What the Research Shows So Far

What is MOTS-c?

MOTS-c stands for mitochondrial open reading frame of the 12S rRNA type-c. It is a 16-amino-acid peptide, MRWQEMGYIFYPRKLR, encoded not in the cell nucleus but in the mitochondrial genome, inside the gene for 12S ribosomal RNA. It was reported by Changhan Lee, Pinchas Cohen and colleagues at the University of Southern California in Cell Metabolism in 2015, and it was the second mitochondrial-derived peptide described after humanin.

That origin is why researchers find it so interesting. Mitochondria were long treated as power plants that take orders from the nucleus. MOTS-c was early evidence that they also send hormone-like signals of their own, and a small, well-defined sequence makes it practical to synthesise and study.

How MOTS-c works: the folate cycle and AMPK

The 2015 paper found skeletal muscle to be the main target. Inside cells, MOTS-c inhibits the folate cycle and the de novo purine synthesis tied to it. That causes a build-up of AICAR, an intermediate that activates AMP-activated protein kinase (AMPK), the cell's main energy-stress sensor. AMPK activation increases glucose uptake and fatty acid use, which links MOTS-c to the same pathway many exercise and metformin studies point to.

A follow-up paper, Kim and colleagues (Cell Metabolism, 2018), showed that under metabolic stress such as glucose restriction, MOTS-c moves into the nucleus in an AMPK-dependent way and regulates nuclear genes, including antioxidant-response genes controlled by NRF2. A peptide made by mitochondria that directly adjusts nuclear gene expression is the finding that made the field take notice.

MOTS-c benefits reported in animal studies

Almost all the mots-c peptide benefits quoted online come from two mouse papers.

• Lee et al., Cell Metabolism, 2015. MOTS-c treatment prevented high-fat-diet-induced obesity and insulin resistance, and reversed age-dependent insulin resistance in muscle.
• Reynolds et al., Nature Communications, 2021. MOTS-c improved physical performance in young (2 month), middle-aged (12 month) and old (22 month) mice. Intermittent treatment started late in life, at 23.5 months, increased physical capacity and healthspan measures. The same paper found exercise raises MOTS-c levels in human skeletal muscle and blood.

That last point is the source of the "exercise mimetic" label. It is a fair description of what happened in mice. It is not evidence that giving MOTS-c reproduces exercise in people, and the gap between those two statements is where most MOTS-c marketing lives.

Human data: CB4211 and the first MOTS-c trial

The only completed human trial of a MOTS-c-based drug used CB4211, an analogue developed by CohBar with properties improved over the native peptide. In the phase 1b stage of a phase 1a/1b study (ClinicalTrials.gov NCT03998514), 20 obese people with nonalcoholic fatty liver disease received CB4211 or placebo by daily subcutaneous injection for four weeks. CohBar reported in 2021 that it was well tolerated with no serious adverse events, that ALT and AST fell by 25 and 17 percent relative to placebo, and that glucose fell, with a trend toward lower body weight. These were exploratory endpoints in a small, short study of a modified molecule.

Native MOTS-c entered its own trial in 2026. A phase 2a study sponsored by Hudson Biotech (NCT07505745), recruiting in China since February 2026, is randomising an estimated 120 adults with prediabetes and overweight or obesity to MOTS-c or placebo for 12 weeks, with insulin sensitivity (Matsuda index) and treatment-emergent adverse events as primary outcomes. At the time of writing, no results have been posted.

MOTS-c side effects and "before and after" claims

There is no published safety dataset for native MOTS-c in humans, so any list of mots-c side effects is guesswork. What can be said: CB4211 caused no serious adverse events in its short trial; the mouse studies did not report toxicity; and because MOTS-c acts through AMPK and glucose handling, blood glucose is the obvious variable a well-designed study would watch. Injection-site reactions are generic to any injected peptide. The Hudson Biotech trial is the first that will measure adverse events for MOTS-c itself.

The same applies to mots-c before and after posts. No human study has published before and after body composition or performance data for MOTS-c. Photos and forum logs have no control group, no verified material and usually several other compounds in play. Our view: MOTS-c is one of the most scientifically interesting peptides on the market, and that is exactly why it deserves to be studied with verified material and proper controls rather than sold on transformation pictures.

Working with MOTS-c in the lab

Chainwell Peptide supplies MOTS-c as 10 mg and 40 mg lyophilised vials. The larger fill suits longer protocols where one lot across the whole study keeps variables fixed. Like most lyophilised peptides, it is best stored frozen or refrigerated, away from light; see our peptide storage guide for the detail and the MOTS-c reconstitution calculator for concentration maths.

Researchers building mitochondrial models often run MOTS-c alongside SS-31, the cardiolipin-targeting peptide, or NAD+ for redox and sirtuin work. The small molecule SLU-PP-332 targets a different exercise pathway, the estrogen-related receptors, and is explained in our SLU-PP-332 explainer. The full mitochondrial research range groups them together.

All of these are sold for laboratory research only, not for human or veterinary use, and nothing on this page is dosing advice. Every vial carries a lot number that matches its certificate on the certificate of analysis lookup, and orders paid before 3pm AEST on a business day are dispatched the same day from within Australia.

Frequently asked questions